This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Youn, C.-K. Articles by You, H. J. Search for Related Content PubMed PubMed Citation Articles by Youn, C.-K. Articles by You, H. J.

Oncogenic H-Ras Up-Regulates Expression of ERCC1 to Protect Cells from Platinum-Based Anticancer Agents

¹ Research Center for Proteineous Materials and ² Department of Pharmacology, School of Medicine, Chosun University, Gwangju, and ³ Department of Pharmacology, School of Medicine, Seoul National University, Seoul, Korea

Tumors frequently contain mutations in the ras genes, resulting in the constitutive activation of the Ras-activated signaling pathway. The activation of Ras is involved not only in tumor progression but also in the development of resistance of the tumor cells to platinum-based chemotherapeutic agents. To investigate the potential mechanisms underlying this resistance, we analyzed the effect of activated H-Ras on the expression of the nucleotide excision repair genes. Here we identified ERCC1, which is one of the key enzymes involved in nucleotide excision repair, as being markedly up-regulated by the activated H-Ras. From promoter analysis of ERCC1, an increase in the Ap1 transcriptional activity as a result of the expression of the oncogenic H-Ras was found to be crucial for this induction. In addition, ERCC1 small interfering RNA expression was shown to reduce the oncogenic H-Ras-mediated increase in the DNA repair activity as well as to suppress the oncogenic H-Ras-mediated resistance of the cells to platinum-containing chemotherapeutic agents. These results suggest that the oncogenic H-Ras-induced ERCC1, which activates the DNA repair capacity, may be involved in the protection of the cells against platinum-based anticancer agents.

This article has been cited by other articles:

				D. Yu, X. Zhang, J. Liu, P. Yuan, W. Tan, Y. Guo, T. Sun, D. Zhao, M. Yang, J. Liu, et al. Characterization of Functional Excision Repair Cross-Complementation Group 1 Variants and Their Association with Lung Cancer Risk and Prognosis Clin. Cancer Res., May 1, 2008; 14(9): 2878 - 2886. [Abstract] [Full Text] [PDF]

				M. Prewett, D. S. Deevi, R. Bassi, F. Fan, L. M. Ellis, D. J. Hicklin, and J. R. Tonra Tumors Established with Cell Lines Selected for Oxaliplatin Resistance Respond to Oxaliplatin if Combined with Cetuximab Clin. Cancer Res., December 15, 2007; 13(24): 7432 - 7440. [Abstract] [Full Text] [PDF]

				L. O. Andrieux, A. Fautrel, A. Bessard, A. Guillouzo, G. Baffet, and S. Langouet GATA-1 Is Essential in EGF-Mediated Induction of Nucleotide Excision Repair Activity and ERCC1 Expression through ERK2 in Human Hepatoma Cells Cancer Res., March 1, 2007; 67(5): 2114 - 2123. [Abstract] [Full Text] [PDF]

				P Ceppi, M Volante, S Novello, I Rapa, K. Danenberg, P. Danenberg, A Cambieri, G Selvaggi, S Saviozzi, R Calogero, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine Ann. Onc., December 1, 2006; 17(12): 1818 - 1825. [Abstract] [Full Text] [PDF]

				Y. Wang, Q.-Y. He, R. W.-Y. Sun, C.-M. Che, and J.-F. Chiu Gold(III) Porphyrin 1a Induced Apoptosis by Mitochondrial Death Pathways Related to Reactive Oxygen Species Cancer Res., December 15, 2005; 65(24): 11553 - 11564. [Abstract] [Full Text] [PDF]

				C.-K. Youn, S.-H. Kim, D. Y. Lee, S. H. Song, I.-Y. Chang, J.-W. Hyun, M.-H. Chung, and H. J. You Cadmium Down-regulates Human OGG1 through Suppression of Sp1 Activity J. Biol. Chem., July 1, 2005; 280(26): 25185 - 25195. [Abstract] [Full Text] [PDF]